Thompson Siegel & Walmsley LLC Makes New Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Thompson Siegel & Walmsley LLC bought a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 12,747 shares of the biotechnology company’s stock, valued at approximately $160,000.

Other large investors have also recently added to or reduced their stakes in the company. KBC Group NV grew its holdings in shares of Rocket Pharmaceuticals by 159.6% in the 4th quarter. KBC Group NV now owns 5,475 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 3,366 shares in the last quarter. E Fund Management Co. Ltd. bought a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at about $139,000. Strategic Financial Concepts LLC bought a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at about $141,000. Private Advisor Group LLC bought a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at about $166,000. Finally, Dana Investment Advisors Inc. grew its holdings in shares of Rocket Pharmaceuticals by 17.5% in the 4th quarter. Dana Investment Advisors Inc. now owns 17,608 shares of the biotechnology company’s stock valued at $221,000 after acquiring an additional 2,627 shares in the last quarter. Institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals Trading Up 3.1 %

Shares of RCKT stock opened at $8.76 on Friday. The firm has a 50 day moving average price of $10.30 and a two-hundred day moving average price of $14.08. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $934.08 million, a PE ratio of -3.19 and a beta of 1.03. Rocket Pharmaceuticals, Inc. has a 12-month low of $8.06 and a 12-month high of $28.67.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.06. As a group, analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current year.

Analyst Ratings Changes

RCKT has been the subject of several analyst reports. Scotiabank raised their price objective on Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a “sector outperform” rating in a report on Monday, March 3rd. BMO Capital Markets began coverage on Rocket Pharmaceuticals in a report on Wednesday. They set an “outperform” rating and a $50.00 price target for the company. Jefferies Financial Group began coverage on Rocket Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $29.00 price target for the company. Needham & Company LLC reduced their price target on Rocket Pharmaceuticals from $52.00 to $42.00 and set a “buy” rating for the company in a report on Friday, February 28th. Finally, Canaccord Genuity Group reduced their price target on Rocket Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a report on Monday, March 3rd. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.00.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.